GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Myriad Genetics Introduces Enhanced Universal Plus Panel for Foresight® Carrier Screen

NextEdge Admin

04 Jun 2024

2 min 11 sec

Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent figure in genetic testing and precision medicine, recently unveiled the Universal Plus Panel as an addition to its Foresight® Carrier Screen. This new panel boasts 39 conditions and screens up to 272 genes linked to severe inherited conditions. The selection of conditions for the Universal Plus panel was guided by the recommendations outlined in the American College of Medical Genetics and Genomics (ACMG) practice resource for carrier screening. ACMG advises expanded carrier screening for individuals contemplating pregnancy, suggesting specific conditions for testing.

Dale Muzzey, Myriad Genetics’ chief scientific officer, emphasized the company’s dedication to enhancing equitable and accessible prenatal care. The incorporation of the Universal Plus panel underscores Myriad’s commitment to ongoing growth and innovation in providing genetic insights for informed family planning decisions. Genes integrated into the panel were chosen based on guideline recommendations, severity of associated conditions, prevalence of conditions, clinical actionability of results, and detection sensitivity.

Myriad’s expanded carrier screen utilizes next-generation sequencing (NGS) and other cutting-edge technologies to detect pathogenic variants associated with heritable genetic diseases, irrespective of ancestry. The Foresight carrier screen delivers a comprehensive report comprising test results and methodology, accompanied by complimentary access to genetic counseling resources. These resources aid families and healthcare providers in comprehending the report and making informed decisions regarding next steps.